Navigation Links
Pharsight's Reporting and Analysis Services Business Reaches Quality Assurance Milestone

New Consulting Unit Hosts Three Customer Audits, Continues Growth Strategy

That Leverages Pharsight's Industry-Leading Software Tools

MOUNTAIN VIEW, Calif., Dec. 20 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that three global biopharmaceutical companies have performed audits of its Reporting and Analysis Services (RAS) unit. The three global drug development organizations that have performed audits of the RAS unit's capabilities are a Top 50 pharmaceutical company, a mid-sized specialty pharmaceutical company, and a leading biotechnology company.

The audits covered RAS operating practices and procedures for study analysis and reporting, RAS facilities, and RAS technology infrastructure. The ability of the RAS unit to support customer quality assurance audits underscores the unit's recently expanded quality assurance capabilities, and reflects the establishment of its quality management infrastructure which expands the types of services RAS can provide to Pharsight customers.

The RAS unit provides pharmacokinetic/pharmacodynamic (PK/PD) analysis and reporting for preclinical and clinical studies, utilizing Pharsight's industry-leading modeling, data management and reporting software tools to provide timely, high-quality analyses supporting sponsors' new drug application submissions. To date RAS has signed consulting agreements for PK/PD analysis and reporting and for population pharmacokinetic modeling with more than 20 pharmaceutical and biotechnology companies.

Since its launch in May 2007, the RAS unit has implemented and validated Pharsight's WinNonlin(R) and WinNonlin AutoPilot(TM) software products to support efficient delivery of non-compartmental analysis and reporting. The RAS group has also more than tripled its staff, including the addition of a Quality Assurance Inspector, and has plans to expand its facilities in Montreal, Canada.

"These recent audits provided third-party evaluations of the ability of our RAS team to deliver quality work in compliance with customer and regulatory expectations, utilizing our market-leading software," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Our RAS unit enables drug developers to meet their growing needs for timely PK/PD modeling. RAS uses our software such as WinNonlin and WinNonlin AutoPilot to deliver submission-quality reports quickly and efficiently. We have created an internal infrastructure that will allow us to take on additional client projects with similar regulatory compliance needs. We believe this infrastructure supports our RAS unit's ability to consistently meet the highest scientific standards, and positions the group to continue serving clients who expect regulatory compliance in the handling of their modeling and simulation projects."

About Pharsight Reporting and Analysis Services

Pharsight's Reporting and Analysis Services (RAS) unit provides a broad spectrum of world-class expertise in pharmacokinetics (PK), pharmacodynamics (PD), statistical analysis, and report writing. RAS scientists make use of Pharsight's industry-leading software tools to provide timely, high-quality analyses and reports for pre-clinical and clinical studies supporting sponsors' new drug application submissions under Module 5 (Clinical Study Reports) of ICH's Common Technical Document for Regulatory Filing. RAS is principally located in Montreal, Canada and serves all major drug development geographies, with business representatives in North America, Europe, and Japan.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at

Forward Looking Statements

The statements in this press release related to the performance and benefits of Pharsight consulting services and software products are forward looking statements. Forward-looking statements are inherently speculative, and actual results may differ materially from Pharsight's expectations due to a variety of factors, including: changes in FDA regulations and customers may not perceive the benefits of Pharsight consulting services and software products to be the same as Pharsight believes them to be. Other risk factors relating to Pharsight are disclosed in the company's most recent Form 10-Q filed with the Securities and Exchange Commission on November 9, 2007. All forward-looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements.

Registered Trademarks and Trademarks

Pharsight, WinNonlin, and WinNonlin AutoPilot are trademarks or registered trademarks of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.

SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. BIO-key(R) Awarded Contract to Deploy Incident Reporting System for Littleton, CO Police Department
2. American Oriental Bioengineering Announces Reporting Date for Third Quarter 2007 Financial Results
3. BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis
4. SeqWright Unveils ABI SOLiD(TM) Next Generation Genetic Analysis System
5. Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
6. Massive reanalysis of genome data solves case of the lethal genes
7. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
8. Gene Codes Corporation Announces Version 4.8 of Sequencher Software for DNA Sequence Assembly & Analysis
9. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
10. Pharsight Expands Strategic Consulting Services Team
11. Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) ... research organisation (CRO) market. The trend of outsourcing ... lower margins but higher volume share for the ... and scale, however, margins in the CRO industry ... (CRO) Market ( ), finds that ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper ... unless it is bound to proteins, copper is also toxic to cells. With ... Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in the ...
Breaking Biology Technology:
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... the "Capacitive Fingerprint Sensors - Technology and Patent ... --> --> Fingerprint ... especially in smartphones. The fingerprint sensor vendor Idex forecasts ... sensor units in mobile devices and of the fingerprint ...
(Date:11/20/2015)... NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... recently interviewed on The RedChip Money Report ... on Bloomberg Europe , Bloomberg Asia, Bloomberg Australia, ... NXTD ) ("NXT-ID" or the "Company"), a biometric authentication ...
(Date:11/19/2015)... Calif. , Nov. 19, 2015  Based on ... Frost & Sullivan recognizes BIO-key with the 2015 Global ... Each year, Frost & Sullivan presents this award to ... line catering to the needs of the market it ... product line meets and expands on customer base demands, ...
Breaking Biology News(10 mins):